Stocklytics Platform
Asset logo for symbol TSHA
Taysha Gene Therapies
TSHA44
$2.39arrow_drop_up46.62%$0.76
Penny Stock
Asset logo for symbol TSHA
TSHA44

$2.39

arrow_drop_up46.62%

Performance History

Chart placeholder
Key Stats
Open$2.08
Prev. Close$1.63
EPS-0.49
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$438.57M
PE Ratio-
LOWHIGH
Day Range1.81
2.42
52 Week Range1.19
4.32
Ratios
EPS-0.49

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Taysha Gene Therapies (TSHA)

Taysha Gene Therapies Inc (TSHA) is a biotechnology company focused on developing and commercializing gene therapies for severe genetic disorders. The company utilizes cutting-edge technologies to deliver transformative treatments to patients with life-threatening conditions. TSHA is committed to addressing the unmet medical needs of patients and improving their quality of life.
TSHA's stock price history shows fluctuations over the years, reflecting the volatility of the biotechnology sector. Investors interested in TSHA should carefully consider the company's financial performance and growth prospects before making investment decisions.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Sean P. Nolan
Headquarters
Dallas
Employees
65
Exchange
NASDAQ
add Taysha Gene Therapies to watchlist

Keep an eye on Taysha Gene Therapies

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the market capitalization of Taysha Gene Therapies (TSHA)?

Taysha Gene Therapies (TSHA) has a market capitalization of $489.81M. The average daily trading volume is 2.21, indicating the stock's liquidity and investor engagement.
help

What is Taysha Gene Therapies 's (TSHA) price per share?

The current price per share for Taysha Gene Therapies (TSHA) is $2.39. The stock has seen a price change of $0.76 recently, indicating a 46.63% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Taysha Gene Therapies (TSHA)?

For Taysha Gene Therapies (TSHA), the 52-week high is $4.32, which is 80.75% from the current price. The 52-week low is $1.2, the current price is 100% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Taysha Gene Therapies (TSHA) a growth stock?

Taysha Gene Therapies (TSHA) has shown an average price growth of -3.67% over the past three years. It has received a score of 10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Taysha Gene Therapies as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Taysha Gene Therapies (TSHA) stock price performance year to date (YTD)?

As of the latest data, Taysha Gene Therapies (TSHA) has a year-to-date price change of 39.77%. Over the past month, the stock has experienced a price change of 20.1%. Over the last three months, the change has been 17.16%. Over the past six months, the figure is -0.42%.
help

Is Taysha Gene Therapies (TSHA) a profitable company?

Taysha Gene Therapies (TSHA) has a net income of -$111.57M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 91.13% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.92K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $15.45M, although specific revenue growth data is currently not available. The gross profit is $14.08M. Operating income is noted at -$71.37M. Furthermore, the EBITDA is -$75.72M.

News

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
GENE THERAPY
BIODISTRIBUTION
RETT SYNDROME
CENTRAL NERVOUS SYSTEM
Oct 22, 2024

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TAYSHA GENE THERAPIES
STOCK OPTION
NEW EMPLOYEE
BIOTECHNOLOGY
Sep 6, 2024

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
CHANGES IN COMPANY'S OWN SHARES
MAJOR SHAREHOLDER ANNOUNCEMENTS
Jun 26, 2024

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
CHANGES IN COMPANY'S OWN SHARES
Jun 25, 2024

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
HEALTH
CLINICAL STUDY
Jun 18, 2024

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
CALENDAR OF EVENTS
HEALTH
Jun 12, 2024

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level